We speculate that it would be beneficial for patients with EGFR+ ovarian tumors that secrete TNFα to consider a combination regime of anti-EGFR mAb, like cetuximab, and TNFα blocking agents. The gene discussed is EGFR; the disease is ovarian neoplasm.